Furthermore, whilst we have provided an initial description of pulldown methods for enriching tumor specific EV-DNA based on differential protein enrichment of EGFR on tumor vs non-tumor EVs, the relevance for these methods for liquid biopsy detection of hypermutation are still not established for GBM. The gene discussed is EGFR; the disease is glioblastoma.